TARGET

The Eurosystem policy response to developments in retail payments

Retrieved on: 
Wednesday, February 7, 2024

Retail payments are undergoing profound changes that are reshaping the European payments landscape.

Key Points: 
  • Retail payments are undergoing profound changes that are reshaping the European payments landscape.
  • The retail payments ecosystem and consumers’ attitudes and preferences are evolving and influencing one another.

Ring Energy Announces Issuance of 2023 Sustainability Report

Retrieved on: 
Thursday, December 28, 2023

THE WOODLANDS, Texas, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Ring Energy, Inc. (NYSE American: REI) (“Ring” or the “Company”) today announced that it has issued its 2023 Sustainability Report (the “2023 Report”), which is available on the Company’s website at www.ringenergy.com under the “Sustainability” tab.

Key Points: 
  • THE WOODLANDS, Texas, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Ring Energy, Inc. (NYSE American: REI) (“Ring” or the “Company”) today announced that it has issued its 2023 Sustainability Report (the “2023 Report”), which is available on the Company’s website at www.ringenergy.com under the “Sustainability” tab.
  • The report provides updated and comprehensive information about Ring’s Environmental, Social and Governance (“ESG”) initiatives and related key performance indicators.
  • During 2022 and into 2023, the Company has executed a number of its targeted ESG initiatives, and these projects are discussed in the 2023 Report.
  • We are confident our 2023 Report showcases our progress on these important fronts.”

Ulta-Lit wins 3-year IP battle but now faces new problem with the same AZ firm

Retrieved on: 
Thursday, December 7, 2023

GLENVIEW, Ill., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Ulta-Lit Tree Company, the leading provider of Christmas light repair products, is battling Simple Living Solutions, LLC (SLS), a company that has infringed Ulta-Lit’s US Patent # 9,500,719. Following Ulta-Lit’s assertion against SLS of this patent in a lawsuit, which was resolved favorably last summer, SLS ceased distribution of the infringing product after an admission of guilt. They will be paying Ulta-Lit monies for 3 more years per contract.

Key Points: 
  • It is used to identify and repair broken incandescent light sets without the need to replace entire strands.
  • “Our Quick Fix for incandescent and insulation piercing for LED are the long-accepted industry standards for rapid and effective repair.
  • That’s like inserting a screwdriver into a live circuit, to what end?”, said John DeCosmo, founder and owner of Ulta-Lit.
  • Ulta-Lit has taken over 10,000 phone calls and emails in 25+ years, striving to keep the consumers’ holidays bright.

A Type of Allergy Medicine Might Help Treat Lung Cancer, Research Suggests

Retrieved on: 
Wednesday, December 6, 2023

NEW YORK, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).

Key Points: 
  • Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).
  • NEW YORK, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Researchers at the Icahn School of Medicine at Mount Sinai have identified an allergy pathway that, when blocked, unleashes antitumor immunity in mouse models of non-small cell lung cancer (NSCLC).
  • "Strikingly, we found that IL-4 blockade enhanced lung cancer response to checkpoint blockade in mice and in six lung cancer patients with treatment-resistant disease.
  • "In our relentless pursuit of progress, the Cancer Research Institute (CRI) proudly supports the visionary team at the Icahn School of Medicine at Mount Sinai.

Target RWE Releases Important Updates on the Cirrhosis Quality Collaborative/TARGET-Liver Disease Partnership with the American Association for the Study of Liver Diseases

Retrieved on: 
Friday, November 10, 2023

DURHAM, N.C., Nov. 10, 2023 /PRNewswire/ -- Real-world evidence (RWE) leader Target RWE announced today that the CQC and TARGET-Liver Disease (LD) partnership with the American Association for the Study of Liver Diseases (AASLD) has enrolled approximately 75,000 patients.

Key Points: 
  • DURHAM, N.C., Nov. 10, 2023 /PRNewswire/ -- Real-world evidence (RWE) leader Target RWE announced today that the CQC and TARGET-Liver Disease (LD) partnership with the American Association for the Study of Liver Diseases (AASLD) has enrolled approximately 75,000 patients.
  • Target RWE has enrolled approximately 75,000+ patients under the TARGET-LD protocol to support AASLD/CQC.
  • The strategic partnership between Target RWE and AASLD is designed to fulfill the unmet need for a large, real-world registry of patients with chronic liver diseases.
  • "These liver diseases are growing in prevalence and are placing a tremendous burden on healthcare systems around the world.

InventHelp Inventor Develops New Football Training Aid (TPL-294)

Retrieved on: 
Tuesday, October 10, 2023

PITTSBURGH, Oct. 10, 2023 /PRNewswire/ -- "I wanted to create a football training aid to help promote the muscle memory and coordination needed for a player to keep his head raised when blocking and tackling," said an inventor, from Toledo, Ohio, "so I invented THE TARGET SHIELD.

Key Points: 
  • PITTSBURGH, Oct. 10, 2023 /PRNewswire/ -- "I wanted to create a football training aid to help promote the muscle memory and coordination needed for a player to keep his head raised when blocking and tackling," said an inventor, from Toledo, Ohio, "so I invented THE TARGET SHIELD.
  • The patent-pending invention provides a realistic and effective training aid for football players.
  • In doing so, it helps teach a football player proper blocking and tackling techniques.
  • The invention features an adjustable design that is easy to use so it is ideal for football players, coaches and teams.

Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole

Retrieved on: 
Monday, October 2, 2023

Prescription Drug User Fee Act (PDUFA) goal date set for April 03, 2024

Key Points: 
  • Prescription Drug User Fee Act (PDUFA) goal date set for April 03, 2024
    Ad hoc announcement pursuant to Art.
  • 53 LR
    Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, announced today that the US Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for the antibiotic ceftobiprole, which was submitted to the FDA on August 3rd this year.
  • The FDA has set April 03, 2024, as the Prescription Drug User Fee Act (PDUFA) goal date.
  • Basilea is planning to commercialize ceftobiprole in the US through a partner and intends to enter into such a partnership prior to the PDUFA goal date.

Banque Delubac & Cie goes live with Finastra to launch its instant payments offering

Retrieved on: 
Monday, September 18, 2023

LONDON, Sept. 18, 2023 /PRNewswire/ -- Finastra, a global provider of financial software applications and marketplaces, announces that Banque Delubac & Cie, an independent financial institution offering specialist banking services, has launched its instant payments offering with Finastra Payments To Go. With the SaaS solution implemented, the bank can provide other institutions with access to Europe's TARGET Instant Payments Settlements (TIPS), while future-proofing its business to respond quickly to changing demands. The solution will also help the bank deliver faster innovation and drive business growth.

Key Points: 
  • With Finastra Payments To Go, Banque Delubac & Cie can offer other financial institutions access to Europe's TIPS
    LONDON, Sept. 18, 2023 /PRNewswire/ -- Finastra , a global provider of financial software applications and marketplaces, announces that Banque Delubac & Cie , an independent financial institution offering specialist banking services, has launched its instant payments offering with Finastra Payments To Go .
  • "Customers expect to make and take payments instantly, seamlessly and securely, 24/7," said Djillali Ouadah, Head of Correspondent Banking at Banque Delubac & Cie. "As transaction volumes continue to grow, we will provide a highly reliable payment processing solution to facilitate instant payments, without compromising security.
  • By reducing complexity and operational costs, institutions can implement new offerings – such as compliance with the proposed EU instant payments regulation – and drive business growth.
  • "Our solution has enabled Banque Delubac & Cie to provide its customers with access to faster, more transparent and inclusive payment services.

Banque Delubac & Cie goes live with Finastra to launch its instant payments offering

Retrieved on: 
Monday, September 18, 2023

LONDON, Sept. 18, 2023 /PRNewswire/ -- Finastra, a global provider of financial software applications and marketplaces, announces that Banque Delubac & Cie, an independent financial institution offering specialist banking services, has launched its instant payments offering with Finastra Payments To Go. With the SaaS solution implemented, the bank can provide other institutions with access to Europe's TARGET Instant Payments Settlements (TIPS), while future-proofing its business to respond quickly to changing demands. The solution will also help the bank deliver faster innovation and drive business growth.

Key Points: 
  • With Finastra Payments To Go, Banque Delubac & Cie can offer other financial institutions access to Europe's TIPS
    LONDON, Sept. 18, 2023 /PRNewswire/ -- Finastra , a global provider of financial software applications and marketplaces, announces that Banque Delubac & Cie , an independent financial institution offering specialist banking services, has launched its instant payments offering with Finastra Payments To Go .
  • "Customers expect to make and take payments instantly, seamlessly and securely, 24/7," said Djillali Ouadah, Head of Correspondent Banking at Banque Delubac & Cie. "As transaction volumes continue to grow, we will provide a highly reliable payment processing solution to facilitate instant payments, without compromising security.
  • By reducing complexity and operational costs, institutions can implement new offerings – such as compliance with the proposed EU instant payments regulation – and drive business growth.
  • "Our solution has enabled Banque Delubac & Cie to provide its customers with access to faster, more transparent and inclusive payment services.

Basilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiprole

Retrieved on: 
Friday, August 4, 2023

The additional successfully completed phase 3 studies in ABSSSI and CABP support the broad clinical utility of ceftobiprole.

Key Points: 
  • The additional successfully completed phase 3 studies in ABSSSI and CABP support the broad clinical utility of ceftobiprole.
  • Provided that the NDA submission is accepted, Basilea expects a decision by the FDA on the NDA in the second quarter of 2024.
  • Basilea plans to commercialize ceftobiprole in the US through a partner and intends to enter into such a partnership prior to the FDA’s decision on the NDA.
  • Basilea has been awarded approximately USD 112 million, or approximately 75 percent of the costs related to the SAB and ABSSSI phase 3 studies, regulatory activities and non-clinical work.